Ayesha N Shajahan-Haq

List of Publications by Year
in descending order

59 papers	7,090 citations	218677 26 h-index	233421 45 g-index
61 all docs	61 docs citations	61 times ranked	17706 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Endoplasmic Reticulum Stress, the Unfolded Protein Response, Autophagy, and the Integrated Regulation of Breast Cancer Cell Fate. Cancer Research, 2012, 72, 1321-1331.	0.9	183
3	Human Xâ€Box binding proteinâ€1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal, 2007, 21, 4013-4027.	0.5	169
4	MYC-Driven Pathways in Breast Cancer Subtypes. Biomolecules, 2017, 7, 53.	4.0	152
5	Autophagy and endocrine resistance in breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 1283-1294.	2.4	137
6	Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness. Cancer Research, 2012, 72, 3337-3349.	0.9	133
7	Novel Mechanism of Endothelial Nitric Oxide Synthase Activation Mediated by Caveolae Internalization in Endothelial Cells. Circulation Research, 2006, 99, 870-877.	4.5	122
8	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research and Treatment, 2019, 175, 595-603.	2.5	106
9	Tyrosine phosphorylationâ€dependence of caveolaeâ€mediated endocytosis. Journal of Cellular and Molecular Medicine, 2007, 11, 1239-1250.	3.6	96
10	BCL2 and CASP8 regulation by NFâ€ÎºB differentially affect mitochondrial function and cell fate in antiestrogenâ€sensitive and â€resistant breast cancer cells. FASEB Journal, 2010, 24, 2040-2055.	0.5	76
11	MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Molecular Cancer, 2014, 13, 239.	19.2	74
12	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 8-20.	2.5	73
13	Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 263-272.	2.5	67
14	The role of X-box binding protein-1 in tumorigenicity. Drug News and Perspectives, 2009, 22, 241.	1.5	64
15	Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity. Journal of Biological Chemistry, 2007, 282, 5934-5943.	3.4	61
16	Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis. PLoS ONE, 2010, 5, e8604.	2.5	60
17	Nitrosationâ€Dependent Caveolin 1ÂPhosphorylation, Ubiquitination, and Degradation and its Association with Idiopathic Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 816-830.	1.7	59
18	Tyrosine-phosphorylated Caveolin-1 (Tyr-14) Increases Sensitivity to Paclitaxel by Inhibiting BCL2 and BCLxL Proteins via c-Jun N-terminal Kinase (JNK). Journal of Biological Chemistry, 2012, 287, 17682-17692.	3.4	58

#	Article	IF	Citations
19	Application of Metabolomics in Drug Resistant Breast Cancer Research. Metabolites, 2015, 5, 100-118.	2.9	50
20	CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities. , 2018, 191, 65-73.		50
21	Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 35-44.	0.7	49
22	GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and Lâ€“Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 448-459.	4.1	49
23	Caveolin-1 regulates cancer cell metabolism via scavenging Nrf2 and suppressing MnSOD-driven glycolysis. Oncotarget, 2016, 7, 308-322.	1.8	42
24	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. Frontiers in Oncology, 2019, 9, 686.	2.8	41
25	The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-9.	1.2	36
26	Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy. Redox Biology, 2022, 52, 102304.	9.0	32
27	Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate. Cancer Research, 2015, 75, 1046-1055.	0.9	31
28	Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 12292.	4.1	31
29	BMRF-Net: a software tool for identification of protein interaction subnetworks by a bagging Markov random field-based method. Bioinformatics, 2015, 31, 2412-2414.	4.1	30
30	EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget, 2017, 8, 96865-96884.	1.8	29
31	Promoting Scientistâ€“Advocate Collaborations in Cancer Research: Why and How. Cancer Research, 2018, 78, 5723-5728.	0.9	27
32	Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer. Interface Focus, 2013, 3, 20130012.	3.0	26
33	Systems Approaches to Cancer Biology. Cancer Research, 2016, 76, 6774-6777.	0.9	26
34	Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. Cancers, 2020, 12, 2647.	3.7	25
35	Breast cancer cell obatoclax response characterization using passivatedâ€electrode insulatorâ€based dielectrophoresis. Electrophoresis, 2017, 38, 1988-1995.	2.4	23
36	Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Genes and Nutrition, 2012, 7, 83-89.	2.5	19

#	Article	IF	Citations
37	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Research, 2016, 44, e65-e65.	14.5	15
38	Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors. Frontiers in Oncology, 2021, 11, 681530.	2.8	15
39	Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition. Journal of the Royal Society Interface, 2020, 17, 20200339.	3.4	12
40	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer, 2021, 127, 3622-3630.	4.1	8
41	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemporary Clinical Trials Communications, 2018, 10, 190-192.	1.1	7
42	SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.. Journal of Clinical Oncology, 2018, 36, 1038-1038.	1.6	7
43	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. Bioinformatics, 2017, 33, 177-183.	4.1	5
44	Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells. Sensors and Actuators B: Chemical, 2018, 277, 186-194.	7.8	3
45	A novel statistical approach to identify co-regulatory gene modules. , 2013, , .		2
46	Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer. Cancer & Metabolism, 2014, 2, .	5.0	1
47	Abstract 1508: Integration of transcriptomic and metabolomic data reveals a central role for EGR1 in regulating survival and cellular metabolism in endocrine-resistant breast cancer. , 2016, , .		1
48	Abstract 1258: The unfolded protein response may contribute to racial disparity in endocrine responsiveness in breast cancer. , 2015, , .		1
49	Abstract 1634: A novel small molecule inhibitor of IRE1alpha reverses endocrine resistance in breast cancer cells. , 2014, , .		0
50	Abstract 679: Glutamine metabolism in MYC-driven antiestrogen resistant breast cancer cells confers metabolic flexibility through the unfolded protein response. , 2014, , .		0
51	Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 183-202.		0
52	Abstract C73: Differences in UPR signaling in ER+ breast cancer between African American and Caucasian women. , 2014, , .		0
53	Abstract B2-09: A systems biology approach to understanding estrogen responsiveness in breast cancer cells using the MCF7 model. , 2015, , .		0
54	Abstract B1-23: Early growth response (EGR1) is a critical regulator of cellular metabolism and predicts increased responsiveness to antiestrogens in breast cancer. , 2015, , .		0

#	Article	IF	Citations
55	Abstract 430: Combination of CB-839 and everolimus is effective in inhibiting growth of endocrine resistant breast cancer in vivo. , 2017, , .		0
56	Abstract 2862: Inhibition of DNA repair pathways in breast cancer is a potential mechanism of action of IT-139. , 2018, , .		0
57	Abstract P3-09-14: Regulation of gene expression and DNA methylation with cytotoxic T lymphocytes evaluation in subtypes of breast cancers. , 2020, , .		0
58	Abstract P1-19-20: Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. , 2020, , .		0
59	Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling. , 2019, , .		0